Share your thoughts, 1 month free Claude Pro on usSee more
WorkDL logo mark

XLSTM-HVED: Cross-Modal Brain Tumor Segmentation and MRI Reconstruction Method Using Vision XLSTM and Heteromodal Variational Encoder-Decoder

About

Neurogliomas are among the most aggressive forms of cancer, presenting considerable challenges in both treatment and monitoring due to their unpredictable biological behavior. Magnetic resonance imaging (MRI) is currently the preferred method for diagnosing and monitoring gliomas. However, the lack of specific imaging techniques often compromises the accuracy of tumor segmentation during the imaging process. To address this issue, we introduce the XLSTM-HVED model. This model integrates a hetero-modal encoder-decoder framework with the Vision XLSTM module to reconstruct missing MRI modalities. By deeply fusing spatial and temporal features, it enhances tumor segmentation performance. The key innovation of our approach is the Self-Attention Variational Encoder (SAVE) module, which improves the integration of modal features. Additionally, it optimizes the interaction of features between segmentation and reconstruction tasks through the Squeeze-Fusion-Excitation Cross Awareness (SFECA) module. Our experiments using the BraTS 2024 dataset demonstrate that our model significantly outperforms existing advanced methods in handling cases where modalities are missing. Our source code is available at https://github.com/Quanato607/XLSTM-HVED.

Shenghao Zhu, Yifei Chen, Shuo Jiang, Weihong Chen, Chang Liu, Yuanhan Wang, Xu Chen, Yifan Ke, Feiwei Qin, Changmiao Wang, Zhu Zhu• 2024

Related benchmarks

TaskDatasetResultRank
Enhancing Tumour SegmentationBraTS 2018 (test)
Dice Score41.62
95
Whole Tumor SegmentationPretreat-MetsToBrain-Masks
Mean Dice56.92
60
Enhancing Tumor SegmentationPretreat-MetsToBrain-Masks
Mean Dice37.02
45
Tumor Core SegmentationPretreat-MetsToBrain-Masks
Dice (Mean)0.3913
45
Enhancing Tumor (ET) SegmentationBraTS 2024
Average Performance Score33.26
40
Whole Tumor SegmentationBraTS 2018 (test)
DSC Average75.15
37
Enhancing Tumor (ET) SegmentationBraTS 2024 (val)
Average Score109.8
20
Tumor Core (TC) SegmentationBraTS 2024 (val)
Average Performance Score109.3
20
Enhancing Tumor SegmentationBraTS 2018 (test)
Sensitivity (ET)75.83
20
Brain Tumor SegmentationBraTS Whole Tumor (WT) 2024
Average Sensitivity (WT)71.95
20
Showing 10 of 26 rows

Other info

Follow for update